1. Scrip
  2. >>Focus On Asia

Singapore Govt Links With GSK, Takeda, Sanofi In Biopharma Manufacturing Boost

New Consortium Formed

 
• By Lisa Takagi

As Singapore aims for growth in its biopharma manufacturing capability, three key players in the pharmaceutical industry announced plans to join a newly-formed public-private consortium designed to foster innovation in the production of vaccines and biologics.

The three firms has already opened or in construction of new manufacturing sites in Singapore
new project aims to boost Singapore's position as biopharma manufacturing hub • Source: Shutterstock

Singapore’s Agency for Science, Technology and Research (A*STAR) has announced a new partnership between its research communities and GSK plc, Sanofi and Takeda Pharmaceutical Co. Ltd. to enhance the country’s biologics manufacturing capabilities, including for recombinant therapeutic proteins and vaccines.

The new alliance with the three major pharma firms, which already have manufacturing sites in the country, will be finalized through the Biologics Pharma Innovation Programme Singapore (BioPIPS), a consortium managed by A*STAR

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

OPPI’s Matai On Section 3(d) Of India’s Patent Regulations: Now’s The Time To Open Up

 
• By Anju Ghangurde

Anil Matai, director general, Organization of Pharmaceutical Producers of India, talks in this audio interview about the evolving intellectual property landscape in India post the 2024 amendments, including long-standing sticking points such as Section 3(d) of India’s patent regulations and innovator firms' experience of the Bolar provision. There’s also a "compelling reason" to consider regulatory data protection, he claims.

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.